|Mr. Robert B. Kay||Exec. Chairman & CEO||310.73k||N/A||77|
|Mr. Robert L. Erwin||Pres||2.3M||N/A||64|
|Mr. James P. Mullaney CPA||CFO & Principal Accounting Officer||86.67k||N/A||46|
|Mr. Terence E. Ryan Ph.D.||Chief Scientific Officer||200k||N/A||62|
|Dr. Renato Lobo||Chief Medical Officer||N/A||N/A||N/A|
iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.
iBio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.